Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick R Appelbaum

Showing results (121-130 of 339) with videos related to

Pageof 34
Sort By:
Haematologica|August 4, 2022
Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemiaCorentin Orvain, Jacob A Wilson, Min Fang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignmentRoland B Walter, Megan Othus, Gautam Borthakur, et al.
Cancer Medicine|July 25, 2020
Regimen-intensity per count-recovery and hospitalization index: A new tool to assign regimen intensity for AMLMohamed L Sorror, Shirali Agarwal, Megan Othus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate modelEneida R Nemecek, Donald K Hamlin, Darrell R Fisher, et al.
British Journal of Haematology|March 4, 2014
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemiaAnjali S Advani, Shannon McDonough, Steven Coutre, et al.
Bone Marrow Transplantation|February 27, 2019
Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remissionColin D Godwin, Jonathan R Fromm, Megan Othus, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 11, 2008
Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromesBart L Scott, J Y Park, H Joachim Deeg, et al.
Leukemia & Lymphoma|August 18, 2012
The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011)Melhem Solh, Kanti R Rai, Bercedis L Peterson, et al.
Blood|November 23, 2006
Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemiaPaul A Carpenter, David S Snyder, Mary E D Flowers, et al.
Leukemia & Lymphoma|December 21, 2020
Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemiaXueyan Chen, Megan Othus, Brent L Wood, et al.
Pageof 34

Showing results (121-130 of 339) with videos related to

Sort By:
Pageof 34
Haematologica|August 4, 2022
Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemiaCorentin Orvain, Jacob A Wilson, Min Fang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignmentRoland B Walter, Megan Othus, Gautam Borthakur, et al.
Cancer Medicine|July 25, 2020
Regimen-intensity per count-recovery and hospitalization index: A new tool to assign regimen intensity for AMLMohamed L Sorror, Shirali Agarwal, Megan Othus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate modelEneida R Nemecek, Donald K Hamlin, Darrell R Fisher, et al.
British Journal of Haematology|March 4, 2014
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemiaAnjali S Advani, Shannon McDonough, Steven Coutre, et al.
Bone Marrow Transplantation|February 27, 2019
Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remissionColin D Godwin, Jonathan R Fromm, Megan Othus, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 11, 2008
Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromesBart L Scott, J Y Park, H Joachim Deeg, et al.
Leukemia & Lymphoma|August 18, 2012
The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011)Melhem Solh, Kanti R Rai, Bercedis L Peterson, et al.
Blood|November 23, 2006
Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemiaPaul A Carpenter, David S Snyder, Mary E D Flowers, et al.
Leukemia & Lymphoma|December 21, 2020
Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemiaXueyan Chen, Megan Othus, Brent L Wood, et al.
Pageof 34